Nutra Pharma Corp. (NPHC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nutra Pharma Corp. (NPHC) with AI Score 61/100 (Hold). Nutra Pharma Corp. is a biopharmaceutical company focused on acquiring, licensing, and commercializing products for pain management, neurological disorders, cancer, and autoimmune diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Nutra Pharma Corp. (NPHC) Healthcare & Pipeline Overview
Nutra Pharma Corp. operates in the specialty and generic drug manufacturing sector, focusing on pain management and neurological disorders. The company commercializes products like Nyloxin and Pet Pain-Away, targeting both human and animal markets with homeopathic and ethical drugs, primarily within the United States.
Investment Thesis
Nutra Pharma Corp. operates with a high profit margin of 1865.7% and a gross margin of 56.8%. The company's focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet could provide growth opportunities. However, the company's OTC listing and small market capitalization present liquidity and transparency concerns. The success of their drug development pipeline, including RPI-78M and RPI-MN, is critical for long-term growth. Investors should closely monitor the company's ability to navigate the regulatory landscape and secure partnerships for commercializing its products.
Based on FMP financials and quantitative analysis
Key Highlights
- Profit Margin of 1865.7% indicates high profitability on sales.
- Gross Margin of 56.8% suggests efficient cost management in product sales.
- P/E Ratio of 0.25 suggests the company may be undervalued relative to its earnings.
- Beta of -2.90 indicates the stock price moves inversely to the market, potentially offering diversification benefits.
- Focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet.
Competitors & Peers
Strengths
- Proprietary formulations for pain relief products.
- Focus on niche markets with limited competition.
- High profit margin of 1865.7%.
- Established brand recognition in specific product categories.
Weaknesses
- Small market capitalization and limited financial resources.
- OTC listing with associated liquidity and transparency concerns.
- Dependence on a limited number of products.
- Limited number of employees (4).
Catalysts
- Upcoming: Clinical trial results for RPI-78M in treating neurological diseases could drive investor interest.
- Upcoming: Potential partnerships with pharmaceutical companies for expanded distribution.
- Ongoing: Expansion of the Nyloxin product line into new markets.
- Ongoing: Increasing sales of Pet Pain-Away in the growing pet healthcare market.
- Ongoing: Regulatory approvals for new indications of existing products.
Risks
- Potential: Intense competition from established pharmaceutical companies.
- Potential: Regulatory hurdles and FDA approval processes.
- Potential: Product liability claims.
- Ongoing: Limited financial resources and small market capitalization.
- Ongoing: OTC listing with associated liquidity and transparency concerns.
Growth Opportunities
- Expansion of the Nyloxin product line into new markets and applications represents a significant growth opportunity. The market for pain relief products is substantial, with a global market size estimated at billions of dollars. By targeting specific pain conditions and demographics, Nutra Pharma can capture a larger share of this market. The company's focus on non-narcotic pain relief alternatives aligns with the growing demand for safer pain management options.
- Development and commercialization of RPI-78M for neurological and autoimmune diseases could be a major growth driver. The market for treatments for conditions like multiple sclerosis and rheumatoid arthritis is substantial, with significant unmet medical needs. Successful clinical trials and regulatory approval could lead to substantial revenue growth for Nutra Pharma. This represents a high-risk, high-reward opportunity with a multi-year timeline.
- Leveraging the Pet Pain-Away product line to capitalize on the growing pet healthcare market. The pet healthcare market is experiencing rapid growth, driven by increased pet ownership and willingness to spend on pet health. By expanding the distribution channels and marketing efforts for Pet Pain-Away, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.
- Strategic partnerships with pharmaceutical companies or distributors to expand the reach of Nutra Pharma's products. Collaborations with established players in the pharmaceutical industry can provide access to larger markets and distribution networks. This can accelerate the commercialization of Nutra Pharma's products and increase revenue growth. Identifying and securing suitable partners is crucial for realizing this growth opportunity.
- Expansion of the Luxury Feet product line into new retail channels and geographic markets. The market for foot care products is substantial, driven by the increasing awareness of foot health and the growing demand for specialized products. By expanding the distribution channels and marketing efforts for Luxury Feet, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.
Opportunities
- Expansion of the Nyloxin product line into new markets.
- Development and commercialization of RPI-78M for neurological diseases.
- Leveraging the Pet Pain-Away product line in the growing pet healthcare market.
- Strategic partnerships with pharmaceutical companies or distributors.
Threats
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and FDA approval processes.
- Potential for product liability claims.
- Changes in consumer preferences and market trends.
Competitive Advantages
- Proprietary formulations for products like Nyloxin and Pet Pain-Away.
- Focus on niche markets with limited competition.
- Established brand recognition in specific product categories.
- Intellectual property rights for certain drug candidates.
About NPHC
Nutra Pharma Corp., incorporated in 2000 and based in Plantation, Florida, is a biopharmaceutical company engaged in acquiring, licensing, and commercializing pharmaceutical products and technologies. The company focuses on homeopathic and ethical drugs aimed at managing pain, neurological disorders, cancer, and autoimmune and infectious diseases, primarily in the United States. Its key products include the Nyloxin line, featuring oral sprays and topical gels designed to alleviate pain associated with lower back issues, migraines, arthritis, and repetitive stress. The company also offers Pet Pain-Away, a homeopathic pain reliever for companion animals, and Luxury Feet, targeting pain from wearing high heels. Additionally, Nutra Pharma is developing RPI-78M for neurological and autoimmune diseases, RPI-MN for viral diseases including HIV/AIDS and herpes, and RPI-78 and RPI-70 for pain and arthritis. The company aims to provide alternative and effective treatments in areas with unmet medical needs.
What They Do
- Acquires and licenses pharmaceutical products and technologies.
- Commercializes homeopathic and ethical drugs.
- Develops treatments for pain management.
- Creates products for neurological disorders.
- Offers solutions for cancer and autoimmune diseases.
- Provides pain relief products for both humans and animals.
Business Model
- Acquires or licenses rights to pharmaceutical products and technologies.
- Manufactures and markets its own branded products, such as Nyloxin and Pet Pain-Away.
- Generates revenue through direct sales and distribution agreements.
- Focuses on niche markets within the pain management and neurological disorder sectors.
Industry Context
Nutra Pharma Corp. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market for pain management products is substantial, driven by an aging population and increasing prevalence of chronic conditions. Companies in this space must navigate complex FDA approval processes and compete with established pharmaceutical giants. Nutra Pharma's focus on homeopathic and niche products differentiates it from larger players, but also presents challenges in terms of market acceptance and scalability.
Key Customers
- Individuals seeking pain relief from conditions like arthritis, back pain, and migraines.
- Pet owners looking for homeopathic pain relief for their animals.
- Retailers and distributors who sell Nutra Pharma's products.
- The United States Military and Veteran's Administration through Nyloxin Military Strength.
Financials
Chart & Info
Nutra Pharma Corp. (NPHC) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 11, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NPHC.
Price Targets
Wall Street price target analysis for NPHC.
MoonshotScore
What does this score mean?
The MoonshotScore rates NPHC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael D. Flax
CEO
Michael D. Flax serves as the CEO of Nutra Pharma Corp. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the acquisition, licensing, and commercialization of pharmaceutical products and technologies. His leadership is focused on driving the growth of Nutra Pharma's product lines and expanding its market presence. He manages a team of 4 employees.
Track Record: Under Michael D. Flax's leadership, Nutra Pharma Corp. has focused on developing and commercializing niche pain relief products like Nyloxin and Pet Pain-Away. He has overseen the company's efforts to expand its product portfolio and explore new therapeutic areas. His tenure has been marked by a focus on achieving profitability and managing the company's limited resources effectively.
NPHC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nutra Pharma Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is also known as the Expert Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining accurate and reliable information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor the company's news releases and investor relations materials.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established history of operations since 2000.
- Development and commercialization of multiple products.
- Focus on specific therapeutic areas with unmet medical needs.
- Existence of intellectual property rights for certain drug candidates.
- Availability of product information and customer testimonials.
Nutra Pharma Corp. Stock: Key Questions Answered
What does Nutra Pharma Corp. do?
Nutra Pharma Corp. is a biopharmaceutical company that acquires, licenses, and commercializes pharmaceutical products and technologies, focusing on homeopathic and ethical drugs for pain management, neurological disorders, cancer, and autoimmune diseases. Their primary products include the Nyloxin line, used for pain relief in humans, and Pet Pain-Away, a homeopathic pain reliever for companion animals. The company also develops novel therapies like RPI-78M for neurological diseases and RPI-MN for viral infections, targeting unmet medical needs in these areas.
What do analysts say about NPHC stock?
As of 2026-03-15, formal analyst coverage of Nutra Pharma Corp. (NPHC) is limited due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 0.25 and a high profit margin of 1865.7%. Growth considerations center on the successful development and commercialization of its drug pipeline and expansion of its existing product lines. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed stocks.
What are the main risks for NPHC?
Nutra Pharma Corp. faces several risks, including intense competition from larger pharmaceutical companies, regulatory hurdles in obtaining FDA approvals, and potential product liability claims. As an OTC-listed company, NPHC also faces liquidity and transparency concerns. The company's limited financial resources and dependence on a small number of products further amplify these risks. Investors should carefully assess these factors before investing in NPHC.
What are the key factors to evaluate for NPHC?
Nutra Pharma Corp. (NPHC) currently holds an AI score of 61/100, indicating moderate score. Key strength: Proprietary formulations for pain relief products.. Primary risk to monitor: Potential: Intense competition from established pharmaceutical companies.. This is not financial advice.
How frequently does NPHC data refresh on this page?
NPHC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NPHC's recent stock price performance?
Recent price movement in Nutra Pharma Corp. (NPHC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary formulations for pain relief products.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NPHC overvalued or undervalued right now?
Determining whether Nutra Pharma Corp. (NPHC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NPHC?
Before investing in Nutra Pharma Corp. (NPHC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.